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Abstract
Background: The amyloidoses are protein misfolding diseases characterized by the deposition of amyloid that leads to cell
death and tissue degeneration. In immunoglobulin light chain amyloidosis (AL), each patient has a unique monoclonal
immunoglobulin light chain (LC) that forms amyloid deposits. Somatic mutations in AL LCs make these proteins less
thermodynamically stable than their non-amyloidogenic counterparts, leading to misfolding and ultimately the formation of
amyloid fibrils. We hypothesize that location rather than number of non-conservative mutations determines the
amyloidogenicity of light chains.
Methodology/Principal Findings: We performed sequence alignments on the variable domain of 50 k and 91 l AL light
chains and calculated the number of non-conservative mutations over total number of patients for each secondary
structure element in order to identify regions that accumulate non-conservative mutations. Among patients with AL, the
levels of circulating immunoglobulin free light chain varies greatly, but even patients with very low levels can have very
advanced amyloid deposition.
Conclusions: Our results show that in specific secondary structure elements, there are significant differences in the number
of non-conservative mutations between normal and AL sequences. AL sequences from patients with different levels of
secreted light chain have distinct differences in the location of non-conservative mutations, suggesting that for patients
with very low levels of light chains and advanced amyloid deposition, the location of non-conservative mutations rather
than the amount of free light chain in circulation may determine the amyloidogenic propensity of light chains.
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Introduction
Amyloidosis is a devastating group of disorders in which
normally soluble proteins misfold and aggregate to form insoluble
amyloid fibrils. Deposition of these amyloid fibrils leads to cell
death and tissue degeneration. To date, more than 20 different
proteins and polypeptides have been identified in disease
associated amyloid deposits. These proteins include the Ab
peptide in Alzheimer’s disease, immunoglobulin light chains in
light chain or primary systemic amyloidosis (AL), and the islet-
associated polypeptide in type II diabetes, among others [1,2]. AL
is the result of a clonal proliferation of monoclonal plasma cells in
the bone marrow. These plasma cells synthesize high amounts of
monoclonal immunoglobulin free light chains (LCs), also known as
Bence Jones proteins (BJP). LCs are secreted into circulation and
excreted in large amounts in urine. While in circulation, the LCs
misfold into amyloid fibrils which in most cases (85%) are
composed of the N-terminal variable domain [3]. The amyloid
fibrils can be deposited in any visceral organ leading to organ
failure and death.
A LC is composed of an N-terminal variable domain (VL) and a
C-terminal constant domain (CL). The VLs are not uniformly
variable throughout their lengths. Three small regions, the
hypervariable regions or complementarity determining regions
(CDR), show much more variability than the rest of the domain.
These regions vary both in size and in sequence among different
VL germline isotypes. These are the regions that determine the
specificity of the antigen-antibody interactions. The remaining
parts of the VL, four framework regions (FRs), have quite similar
amino acid sequences.
The overall structure of the VL is an immunoglobulin fold with
9 b-strands (A, B, C, C9,C 0, D, E, F, and G) packed tightly against
each other in two antiparallel b sheets joined together by a
disulfide bridge. The N- and C- termini strands (A and G,
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b-barrel. The CDRs form three loops between amino acids 24–34,
50–56 and 89–95 that contain the amino acids that will recognize
the antigen (Figure 1). Immunoglobulin quaternary structure
consists of two heterodimers formed by the LC and the
immunoglobulin heavy chain (HC) interacting together via
disulfide bonds. The LC VL domain interacts with the HC
variable domain through b-strands C, C9, F and G. The source of
sequence variability in LCs comes from combinatorial pairing of
the V genes (40 k and 33 l) and the J genes (corresponding to
strand G or FR4), making it possible to generate about 3000
different LC sequences. In addition, further sequence variation
appears from somatic mutations to improve the affinity of the
antibody for the antigen.
In AL, l is overrepresented (3:1) as compared to healthy
individuals or multiple myeloma patients (l/k=1:2), especially the
l VI subtype [5]. In addition, VL germline donor gene usage in
AL is biased [6,7]. The three studies by Comenzo, Abraham and
Prokaeva agree that in AL, the VL germline donor gene usage
comprises Vl II 2a2, Vl III 3r, Vl VI 6a, Vk I O18/O8, while
there are slight differences in the sample size, sample selection and
the frequency of use of each germline donor gene in each study.
Comenzo and co-workers demonstrated 30% of AL VL genes
used Vl VI 6a germline donor [6]. Abraham and co-workers
found that most k patients selected for their study used the Vk I
subgroup (77%) [7]. A similar observation has been made by
Prokaeva and co-workers [8].
Current evidence suggests that AL proteins are less stable than
their non-amyloidogenic counterparts [9,10]. There are several
possible sources of protein destabilization for AL proteins: 1)
somatic mutations that cause the protein to sample partial
unfolded states, 2) proteolytic cleavage that removes the constant
domain, and 3) loss of the interaction with the HC due to
mutations or truncations in LC or HC. Somatic mutations have a
global destabilizing effect on AL proteins and as a consequence
these proteins require less energy to unfold [11–13]. The
propensity to form amyloid fibrils in vitro for some VLs appears
to be inversely correlated with their free energy of unfolding,
suggesting that both stabilizing and destabilizing interactions
within the VL domain can influence the kinetics of amyloid
formation [9,10,14]. The goal of our study was to determine the
nature and the location of mutations in k and l VL sequences
from AL patients and to identify patterns in the location of non-
conservative mutations that correlate with clinical parameters,
such as serum free light chain levels, that may help predict rate of
amyloidogenesis.
Results
A total of 46 AL sequences from Mayo, 48 AL sequences from
Comenzo, and 47 AL sequences from Prokaeva were used for this
study (for a detailed description of the sequences used, see the
Methods section). Analysis of the mutational ‘hot spots’ was
performed separately for AL k and AL l light chains. Figure S1
and Figure S2 show the sequence alignments of 50 AL Vk protein
sequences. As expected, the CDR regions of these VL proteins
have accumulated a large number of somatic hypermutations. For
the Vk proteins in particular, positions 30 (CDR1), 93 (CDR3)
Figure 1. VL structure. A) Topological Diagram of the protein structure for AF490909 adapted from Schiffer, et al [28]. The two b-sheets of the
domains have been separated. Residues that point towards the core are circled. CDR segments are highlighted in yellow. The b-strands have been
encased within the arrows and are connected to their respective loops. B) Structural model of a VL (1BRE.pdb) showing CDR regions in pink, b-hairpin
between strands D and E in blue and dimer interface in green ribbons.
doi:10.1371/journal.pone.0005169.g001
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appeared to be mutational hotspots. No clear bias is observed in
terms of amino acid substitution. For the 91 AL Vl proteins, Vl
I–III sequences (Figure S3 and Figure S4) were analyzed
separately from the Vl VI (Figure S5) sequences. Somatic
hypermutations accumulate in different positions depending on
the germline. Vl I positions 27 (CDR1), 38 (FR2, b-strand C), 50
(FR2), 52 (CDR2), and 95a (CDR3) appear to be mutational
hotspots. Vl II positions 47 (FR2, b-strand C9), 52 (CDR2), 89
(FR3, b-strand F) and positions 92–95b (CDR3) show a
predominance in somatic hypermutation. Vl III positions 31a
(CDR1), 52 (CDR2), and 95a (CDR3) show great variability.
Finally, the Vl VI sequences show mutations in positions 43
(FR2), 52 (CDR2), and in the FR4 region between 95ab–96. All of
the control sequences analyzed in this study showed less
prevalence of mutational ‘hotspots’ in the positions found for AL
sequences (Figure S6, S7, S8, S9).
The majority of the AL Vl sequences in this study had a ratio of
non-conservative over total mutation between 0.6–0.79, while the
majority of AL Vk sequences had a ratio between 0.4–0.59
(Table 1, Figure S10). Further analysis was performed comparing
the proportion of conservative versus non-conservative mutations
in all of our sequence groups (Table 2). Our data indicates that AL
Vl sequences have the widest range of non-conservative and total
number mutations compared to all of the other sequence groups.
When the number of non-conservative mutations per secondary
structure over total number of patients for each germline group
was calculated, no distinct pattern could be discerned between Vk
and Vl, although the Vk sequences showed a lower number of
non-conservative mutations compared to Vl sequences through-
out the VL structure (Figure 2). The CDR regions accumulated
more non-conservative mutations than any other region, in
particular both CDR1 and CDR3 for AL Vk and Vl.
Because Vl VI sequences are virtually always found in amyloid
producing clones, the ratio of non-conservative mutations over
total number of patients for Vl VI versus VlI, II and III was
analyzed (Figure 2C). The overall pattern for the Vl I, II, and III
proteins follows the same trends as the total Vl group of sequences
in Figure 2B. The Multiple Myeloma sequences follow the trend of
the normal Vk for the most part (Figure 3 and Figure S11). The
Vl VI proteins accumulate non-conservative mutations in loop C–
C9 (part of CDR2) with 83% of patients with mutations in this
region and presenting an absence of non-conservative mutations in
loop A–B and loop D–E (structural representation of differences in
Vl is shown in Figure 4). High numbers of non-conservative
mutations are found in b-strands A and G in all Vl proteins; b-
strand G has more non-conservative mutations in Vl VI
sequences. All of the control sequences show comparable levels
of non-conservative mutations among each other.
Comparison of normal and AL sequences showed some
interesting trends. Both the differences in the total number of
mutations as well as the number of non-conservative mutations
between normal sequences and AL Vk are significant for loop C–
C9 (p,0.0302 for total and p,0.0793 for non-conservative) and b-
strand C9 (p,0.012 for total and p,0.006 for non-conservative).
In the case of Vl, the difference in the total number of mutations
between normal and AL Vl sequences for loop C–C9 is significant
(p,0.0432) and so is the number of non-conservative mutations in
b-strand C (p,0.108). We were interested in determining if
Multiple Myeloma sequences would have significant differences in
the location of non-conservative mutations compared to AL
sequences. Multiple Myeloma is a plasma cell hematologic
malignancy (as AL) but does not present amyloid deposits. In
addition, Multiple Myeloma proteins have been used as non-
amyloidogenic controls in biophysical studies [9,10]. We found a
significant difference in the total number of mutations between
Multiple Myeloma and AL Vk sequences in loop C–C9
(p,0.0919).
To test whether mutational patterns correlate with clinical
parameters, sequences from 30 Mayo patients, who had serum
free light chain (FLC) levels measured were further studied.
Patients were divided into three groups based on the concentration
Table 1. Comparison of range of the fraction of non-conservative mutations/ total for all AL Vl,Vk, Mayo, Comenzo and Prokaeva
Vl VI, and all Vl VI proteins.
Range fraction non
conservative
mutations/total Total Vl proteins Total Vk proteins Mayo Vl VI proteins Comenzo Vl VI Prokeva Vl VI Total Vl VI
0.8–1.0 11 10 3 1 1 5
0.6–0.79 47 15 6 7 5 18
0.4–0.59 32 17 3 8 2 13
0.2–0.39 0 8 0 0 0 0
0.0–0.19 1 0 0 0 0 0
The fraction of non-conservative mutations over total mutations were calculated for each patient and then classified according to their range.
doi:10.1371/journal.pone.0005169.t001
Table 2. Comparison of the ranges of non-conservative of mutations and total number of mutations for all the protein sequences.
Mutations AL-Vk AL-Vl Normal- Vk Normal Vl Multiple Myeloma
Non-Conservative Mutations 2–15 3–30 0–22 2–15 0–13
Total Mutations 3–18 4–38 1–32 2–17 2–18
The ranges of total mutations as well as the non-conservative mutations were calculated for each protein group including: AL-Vk, AL-Vl, Normal Vk, Normal Vl,a n d
Multiple Myeloma.
doi:10.1371/journal.pone.0005169.t002
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Group I corresponded to low levels of iFLC (less than 10 mg/dL,
including some patients with normal levels of iFLC, see methods
section for the specific range); group II had intermediate levels
(between 10.1–100 mg/dL) and group III had high levels of iFLC
(above 100 mg/dL). A statistically significant difference in the
number of non-conservative mutations was found among groups
in b-strand A (p,0.03) and b-strand F (p,0.1). Group I and II
present a large number of non-conservative mutations in b-strand
A while group III had a high number of mutations in b-strand F.
The only common region for absence of non-conservative
mutations in all groups is loop D–E (Figure 5). The mutations in
b-strand A for group I and II occur for the most part in amino acid
positions pointing towards the surface of the protein. There is only
one example where the mutation occurs in position 4 and the side
chain points towards the protein core.
There are many other regions that present unique patterns of
high or low ratios of non-conservative mutations among the
groups, but these regions do not attain statistical significance due
to the small percentage of patients in each group with mutations
in a given region (Figure 5). For example, a high number of non-
conservative mutations were found for group I in b-strand B, loop
C–C9 and b-strand C9. Group II and group III show a low
number of mutations in these regions. The different germline
types represented in these groups along with the regions of either
high or low mutation accumulation in each group are shown in
Figure 6.
A more detailed analysis of the types of non-conservative
mutations seen in each protein was performed for group I. The 6
proteins in group I had a total of 49 mutations, 20 of which were
considered conservative and 29 of which were considered non-
conservative. Change in charge was the most common mutation
(15 of 29) with gain of charge as the most frequent change of this
group (9 of 15).
Discussion
The results of our study showed that non-conservative mutations
tend to accumulate in specific structural regions of the AL Vk and
Vl sequences. Comparisons between normal and AL sequences
identified discrete regions that have significantly higher numbers of
mutations in the amyloidogenic sequences. The most interesting
finding is that levels of iFLC at diagnosis corresponded with specific
locations of non-conservative mutations in these sequences. AL is a
protein misfolding disease with enormous mutational diversity.
Efforts to understand the molecular determinants of amyloid
formation for AL proteins could only be conducted in a large basis
using sequence analysis of the subtypes in a separate fashion since k
Figure 2. Non-conservative mutations over total number of patients for each secondary structure element for AL Vl and Vk
proteins. The x-axis shows the different elements of secondary structure in the VL, while the y-axis gives the ratio of non-conservative mutations in
each secondary structure element per total number of patients. The secondary structure boundaries used were based on the germline donor for each
protein. Numbering is based on Kabat (http://vbase.mrc-cpe.cam.ac.uk/). A) Vk sequences. B) Vl sequences. C) Comparison of Vl VI and other
lambdas (Vl I, II and III). The percentage of patients with mutations (% PWM) in each secondary structure element is listed per group.
doi:10.1371/journal.pone.0005169.g002
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Stevens analyzed more than 100 k1 AL LC family sequences from a
larger sequence database, including 370 k and l LC entries [16].
He identified four structural risk factors for k1 VL domains that
may enhance the amyloidogenicity of LCs. These risk factors are:
mutations in the isoleucine at position 27b; mutations in the amino
acid at position 31 that change it to aspartic acid (both amino acids
are located in the CDR1); mutations in Arginine 61 (located in
strand D, part of b-hairpin DE), and the creation of glycosylation
sites (Asparagine-X-Serine/Threonine) anywhere in the protein
sequence. Our unique study compares VL sequences from AL
patients by looking into the number of non-conservative mutations
per secondary structure, extending the previous studies carried out
so far by Stevens [16] to a new level. One important finding in our
study is the fact that the number of mutations, total or non-
conservative per protein, is not enough information to truly begin to
understand the role of mutations in AL since Vk normal controls
present a wider range of non-conservative mutations compared to
AL Vk sequences (Table 2). We believe that it is essential to
determine the number of non-conservative mutations over total
number of patients per secondary structure in specific patient
groups in order to extract useful information that could become
relevant to the understanding of this disease. Our results also show
that even though most mutations among AL proteins are non-
conservative, some of the mutations present in their LCs are
conservative andthereforemaynotaffectthe stabilityof the protein.
In addition, our results show that proteins grouped by iFLC
levels clearly show distinct patterns in the location of non-
conservative mutations. The statistical significance of the high
number of non-conservative mutations in b-strand A (high number
of non-conservative mutations in group I and II, absence of non-
conservative mutations in group III) suggests that this region may
play an important role in amyloidogenesis and is in agreement
with studies from the Solomon group describing b-strand A as part
of the cryptic epitope of VL for a monoclonal antibody against AL
fibrils [17]. It is thought that over-expression of an amyloidogenic
protein may increase the rate of amyloid formation and therefore
will cause disease progression. The difference in the pattern of
non-conservative mutations at different levels of iFLC suggests that
non-conservative mutations in key areas of the immunoglobulin
light chain may affect the rate of amyloidogenesis of the protein. It
suggests the possibility that patients can have different amyloid
formation rates despite similar light chain synthesis rate. Proteins
with mutations identified in the group I patients may have the
highest amyloid formation rates. As it has been published before
[18], high iFLC levels may be associated with more advanced
disease. Our results are the first indication that patients with low
iFLC, which may appear to be at a lower risk for advanced
disease, may be susceptible for amyloid formation because of the
location of mutations in their proteins.
High numbers of non-conservative mutations in b-strand A
were also observed in all Vl. While it may appear that group I and
Figure 3. Non-conservative mutations over total number of patients for each secondary structure element for normal control Vl,
Vk, and multiple myeloma control proteins. The x-axis shows the different elements of secondary structure in the VL, while the y-axis gives the
ratio of non-conservative mutations in each secondary structure element per total number of sequences. The secondary structure boundaries used
were based on the germline donor for each protein. Numbering is based on Kabat (http://vbase.mrc-cpe.cam.ac.uk/). A) Vk normal control sequences.
B) Vl normal control sequences. C) Multiple Myeloma control sequences (combined Vl and Vk). The percentage of sequences with mutations (%
PWM) in each secondary structure element is listed per group.
doi:10.1371/journal.pone.0005169.g003
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non-conservative mutations have been observed in b-strand A in
proteins from group II that are not Vl.
Interestingly, some secondary structure elements completely
lacked non-conservative mutations, such as b-strand F for group I.
One way to explain this result is the fact that non-conservative
mutations may matter more in certain secondary structure
elements than others, thus presence or absence of non conservative
mutations in certain types of proteins may not be relevant.
Significant differences were found between normals and AL Vk
and Vl proteins in loop C–C9. This is an interesting finding since
we have recently published crystallographic studies in which we
propose that loss of interactions within loop C–C9 (also called the
Proline-40 loop) could be involved in the initial conformational
changes leading to amyloid formation [19].
The unique pattern of non conservative mutations found in this
study may have future implications in the treatment of AL patients
given that knowledge of the position of non-conservative mutations
could potentially be used as a marker for disease progression and
response to therapy.
In conclusion, the study of the position of non-conservative
mutations could not only help us understand the molecular
mechanisms in amyloid formation for AL, but it has the potential
to become a new prediction tool for AL disease progression and
response.
Materials and Methods
Ethics statement
The study was carried out under an institutional review board
(IRB)-approved protocol and followed the Helsinki guidelines for
research of human subjects.
Sequence sources
Available sequences were selected from the Abraham, Co-
menzo, Prokaeva, Arendt, Wally, and Sikkink studies in an
unbiased way. The only requirements were that the cDNA
sequence was unambiguous (did not contain unassigned ‘N’
nucleotides) and complete (included the entire VL domain starting
from the FR1 down to the FR4). Sequences obtained from
Abraham, Sikkink, and Arendt studies will be referred to as Mayo
sequences, those obtained from Comenzo and Wally will be
referred to as Comenzo sequences in this article. The Prokaeva
group comes from Prokaeva et al 2007 [8]. We sequenced two
additional proteins in order to incorporate more Vl VI sequences
that were underrepresented from the Mayo cohort of sequences. A
total of 55 Vl I, II and III sequences were used in this study,
which were obtained from Abraham, Comenzo, Prokaeva and
Sikkink publications. The GenBank accession numbers for the Vl
I, II and III from Abraham et al 2003 [7] include: AF490938,
AF490940, AF490941, AF490944, AF490945, AF490949,
AF490952, AF490953, AF490955, AF490958, AF490960, and
AF490961. AY730911 and AY730938 are from Abraham et al
2007 [20]. The GenBank accession numbers for Vl I, II and III
from Comenzo et al 1998 publication [21] include: AF124170,
AF124163, AF124165, AF124164, AF124172, AF124176,
AF124173, AF124171, AF124175, AF124174, and AF124186.
We included the following sequences from Comenzo et al 1999
[22]: AF054641, AF054640, AF115347, AF054638, AF115350,
AF115349, AF115354, and AF054647. AF320832, AF320833,
and AF320834 are from Comenzo et al 2001 [6]. The sequences:
ABU90545, ABU90717, ABU90728, ABU90727, ABU90724,
ABU90719, ABU90703, ABU90725, ABU90704, ABU90701,
ABU90548, ABU90705, ABU90553, ABU90552, ABU90550,
ABU90732 and ABU90723 were from Prokaeva et al. 2007 [8].
The GenBank accession numbers for Vl I, II and III from Sikkink
et al [23] include: DQ240234 and DQ240235.
There were also 50 Vk sequences used for comparison in this
study, which were obtained from Abraham, Comenzo, Prokaeva,
Sikkink and Wally publications. The GenBank accession numbers
for the Vk sequences from Abraham et al 2003 [7] include:
AF490909, AF490910, AF490912, AF490913, AF490916,
AF490920, AF490921, AF490925, AF490929, AF490908,
AF490917, AF490922, AF490907, AF490911, AF490924, and
AF490937. We included AY701640 from Abraham et al 2007
[20]. The sequences ABU90544, ABU90674, ABU90662,
ABU90652, ABU90647, ABU90625, ABU90604, ABU90716,
ABU90653, ABU90600, ABU90599, ABU90712, ABU90644,
ABU90636, ABU90633, ABU90602, ABU90598, ABU90713,
ABU90663, ABU90648, ABU90646, and ABU90637 are from
Prokaeva et al. 2007 [8].The sequence DQ240237 from Sikkink et
Figure 4. Structural models showing the common locations of
non-conservative mutations in ALVl proteins in our study.
Protein models were based on the crystal structure for Vl VI germline
(2CDO.pdb). The b-strands in the structure are shown as red ribbons;
mutation regions discussed in the captions are shown in green.
doi:10.1371/journal.pone.0005169.g004
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myeloma. The patient has since evolved to AL. The Genbank
accession numbers for the Vk sequences from Comenzo et al 1998
[21] include: AF124197, AF361758, and AF124193, AF1156361,
AF054662, AF054661, AF054658, and AF054656 from Comenzo
et al 1999 [22] and AF320835 from Comenzo et al 2001[6]. We
included AF113887 from Wally et al 1999 [24].
A total of 36 Vl VI were used in this study. The Vl VI
sequences obtained for the study were from Abraham, Comenzo,
Prokaeva, and Arendt publications. Two of the cDNA sequences
for Vl VI were done in our laboratory. The Gen Bank accession
numbers for the Vl VI from Comenzo et al 1998 [21] include:
AF124189, AF124184, AF124181, AF124190, AF124187, and
AF124185; sequences from Comenzo et al 1999 [22] include:
AF115360, AF115358, AF115357, AF054653, AF054651, and
AF054649; and the sequences AF320840, AF320839, AF320838,
and AF320837 were from Comenzo et al 2001[6]. The Vl VI
sequences obtained from Abraham et al 2003 [7] include:
AF490966, AF490967 and AF490968. The Vl VI sequences
obtained from Abraham but not yet published include: EF710984,
EF710878, EF711037, EF710969, EF710946, and AY793337.
The following sequences: ABU90551, ABU90549, ABU90726,
ABU90722, ABU90720, ABU90711, ABU90707, and ABU90699
were from Prokaeva et al 2007 [8]. FJ200244 was published by
Arendt et al 2008 [25], and the Vl VI sequenced in our laboratory
for this study are: FJ172996 and FJ172997.
Normal control proteins were selected from the NCBI website:
http://www.ncbi.nlm.nih.gov/sites/entrez?db=Protein&itool=-
toolbar by searching ‘‘human immunoglobulin light chain antibody
NOT amyloidosis’’. The Vk sequences include: CAA66157,
CAA66153, CAA59989, CAA59988, AAX14398, AAB49705,
BAH03699, CAA39072, BAF64543, AAC02819, AAB41730,
AAA20168, AAA20167, AAA20163, BAH03697, BAH03696,
AAA20160, AAB49706, AAA20158, CAE54366, AAD29271,
AAB41731, AAA20165, CAE54365, CAE54364, CAE54363,
CAE54362, CAE54361 and AAD14088. The Vl sequences
include: AAA59018, AAC08342, AAC06030, CAA65054,
BAA19564, BAA19562, CAA36351, AAC08338 and AAA75556.
Some Multiple Myeloma protein sequences were also used for
comparison. These sequences include: 1CD0.pdb (Multiple
Figure 5. Comparison of non conservative mutations per total number of patients for low (I), medium (II) and high (III) iFLC levels in
selected Mayo proteins per secondary structure. iFLC levels have been shown to be a good clinical parameter to follow disease progression
[15,18]. The sequences were gathered into three groups based on their iFLC levels at the time of diagnosis. Whenever there is no data shown for a
particular group/secondary structure element, the value is zero. The secondary structure boundaries used were based on the germline donor for each
protein. Numbering is based on Kabat (http://vbase.mrc-cpe.cam.ac.uk/). The %PWM in each secondary structure element is listed per group.
doi:10.1371/journal.pone.0005169.g005
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protein GAL as published by Kim et al. 2000 [10], 1lve.pdb (LEN),
AY701647, AY701035, AY730974, AY701728, AY701699, and
DQ240236.
Some of the AL cDNA samples were re-sequenced in our
laboratory because the sequences were not complete in GenBank
and we had access to the cDNA. The GenBank accession numbers
for these sequences are: AF490938, AF490960, AF490911,
Figure 6. Structural models showing regions of high and low non-conservative mutation accumulation in iFLC level groups. Protein
models were based on the crystal structure for Vl VI germline (2CDO.pdb). The b-strands in the structure are shown as red ribbons; mutation regions
discussed in the captions are shown in green.
doi:10.1371/journal.pone.0005169.g006
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been updated in GenBank.
VL cDNA sequencing
For the sequences determined in our laboratory, bone marrow
(BM) aspirates were collected previously as described in Abraham
et al 2003 [7] from patients with biopsy-proven AL who were seen
in the Hematology Division at the Mayo Clinic. Briefly, the
marrow preparations were layered on Ficoll Paque to remove red
blood cells, and the mononuclear cells were washed and frozen at -
80uC. Total RNA was extracted from the cells using Trizol
Reagent. The RNA was then used for cDNA preparation using
Superscript reverse transcriptase. Since we had at least partial
cDNA sequences for these patients, 59 primers were designed to
target the specific leader sequence for the germline of these
patients along with a 39 constant region primer for l or k. The
degenerate primers used in this study were previously reported by
Abraham et al. 2003 [7] based on the primers initially reported by
Welschof et al. 1995 [26]. Most of the specific primers used in this
study were published by Abraham et al. 2003 [7]. In addition, we
used the following primers from Comenzo et al. 2001 [6]:
VL3 3r ATG GCA TGG ATC CCT CTC TTC
VL6 6a ATG GCC TGG GCT CCA CTA CTT
These additional primers were designed and used in this study:
VL1 1e ATG GCC TGG TCT CCT CTC CTC
VK2-A17 ATG AGG CTC CCT GCT CAG CTC CTG
VK1-L1 ATG GAC ATG AGA GTC CTC GCT CAG
VKIV B3 GGA TCT CTG GTG CCT ACG GGG
The appropriate DNA band was cut and purified using the
Qiagen QIAquick gel extraction kit. The PCR product was cloned
into pCR2.1 TOPO using the TOPO TA cloning kit from
Invitrogen. Twelve of the resulting clones were sequenced with
forward primers at the Mayo Molecular Biology Sequencing Core
Facility. The clonal VL gene was determined if one gene was
clearly overrepresented in each patient and the protein sequences
were identical in at least five PCR products. The clonal nature of
the Comenzo sequences was determined in a similar manner. In
the case of the Prokaeva sequences, the clonal sequence was
determined by the identity of at least 50% of 6–9 independently
cloned and sequenced products.
DNA sequences obtained were analyzed using DNAPLOT
from the VBase website (http://vbase.mrc-cpe.cam.ac.uk/). This
database uses all known human light chain germline sequences to
assign germline donors based on comparison of the sequences for
the most nucleotide homology.
Structural Characterization of VL Sequences
Once a germline donor was assigned, the sequence of each
protein was modeled on known light chain structures using the
Swiss-PdbViewer 3.7 from the website http://www.expasy.org/
spdbv/. Crystal structures have been reported for kI (O18/O8)
(1B6D.pdb), kII (2AI0.pdb), k IV (1LVE.pdb), l2b2 (1JVK.pdb)
and lVI (2CD0.pdb) proteins, so we aligned the remaining
germline sequences with those germline sequences represented in
the crystal structures using BLAST2 (http://www.ncbi.nlm.nih.
gov/blast/bl2seq/wblast2.cgi) to find the best match for structural
modeling. The kI (O18/O8) crystalstructure was used for all kI and
kIII sequences;kIIandkIVproteinsequenceshavetheirowncrystal
structure representatives. The Vl VI crystal structure was used for
the Vl III, Vl VI, VII, and IX sequences. The Vl II (2b2) crystal
structure was used for all Vl I and Vl II sequences. The b-strands
and loops were assigned using the secondary structure information
from spdb viewer, but the numbering used was according to Kabat
from the VBase website (http://vbase.mrc-cpe.cam.ac.uk/). Each
patient protein sequence was aligned with their own germline
sequence, mutations were identified and highlighted and then
examined to determine the secondary structure location of the
mutations. The AL Vl proteins were divided to compare the Vl VI
proteins to all the other Vl proteins (Vl I, II, and III). Conservative
mutations were those that had similar chemistry (polar to polar,
similar charge, and similar size). We also considered a mutation
from valine, leucine, and isoleucine to/from phenylalanine to be
conservative based on the hydrophilicity measured using side chain
analogues by Radzicka and Wolfenden [27]. Non-conservative
mutations were those that resulted in a change in charge, change in
hydrophobicity, change in side chain size, and inclusion/replace-
ment of proline or glycine. We divided the number of non-
conservative mutations found per secondary structure by the total
number of patients in that specific group. The same pattern of high
and low non-conservative mutations values were found when we
multipliedthenumberofnon-conservativemutationstimestheratio
of patients with non-conservative mutations over the corrected total
number of patients in a given category. We also calculated the ratio
of non-conservative mutation over total number of mutations, but
this ratio did not represent the true distribution of patients among a
specific group.
To test whether mutational position determines amyloidogen-
esis, AL patients with different levels of circulating serum free light
chain at the time of diagnosis were identified. Serum free light
chains were measured using the Freelite
TM Serum Free Light
Chain Assays (The Binding Site Inc., San Diego, CA). Normal
range for k is 0.33 to 1.94 mg/dL and 0.57 to 2.63 mg/dL for l.
Measurements were made with serum samples taken closest to the
time of diagnosis. Patients were separated in groups based on the
levels of the pathologic iFLC. The cutoffs for each group were
assigned based on the logarithmic increments. The low level group
had iFLC #10 mg/dL (including patients with iFLC within
normal ranges listed above), 10.1 to 100 mg/dL in the
intermediate group and .100 mg/dL for the high group.
Supporting Information
Figure S1 Sequence alignment of AL VkI O18/O8, L1 and
VK1106*01. All protein sequences were grouped based on the
dominant clone identified in a given patient’s bone marrow sample.
For k sequences, secondary structure was based on k light chain
protein models kI (1B6D.pdb), kII (2AI0.pdb) and k IV
(1LVE.pdb), using Swiss Protein Database Viewer. For Vl proteins
(I, II, III) and Vl VI proteins secondary structure was based on Vl
protein model (1JVK.pdb) and (2CD0.pdb) using Swiss Protein
Database Viewer, respectively. Numbering for the secondary
structure was based on Kabat (http://vbase.mrc-cpe.cam.ac.uk/).
Sequences are called according to their GenBank numbers. Bold
sequences correspond to the germline donor sequence. Yellow
highlights denote somatic mutations present in the sequences.
Found at: doi:10.1371/journal.pone.0005169.s001 (0.95 MB TIF)
Figure S2 Sequence alignment of AL VkI L12, 012/02, L5, and
VkIV B3. Structure determination and mutation analysis were
done as described in Figure S1.
Found at: doi:10.1371/journal.pone.0005169.s002 (0.75 MB TIF)
Figure S3 Sequence alignment of AL VlI 1c, 1b and 1e.
Structure determination and mutation analysis were done as
described in Figure S1.
Found at: doi:10.1371/journal.pone.0005169.s003 (0.87 MB TIF)
Figure S4 Sequence alignment of AL VlII 2b2, 2a2, 2c, and
VlIII 3r. Structure determination and mutation analysis were
done as described in Figure S1.
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Figure S5 Sequence alignment of AL VlVI 6a. Structure
determination and mutation analysis were done as described in
Figure S1.
Found at: doi:10.1371/journal.pone.0005169.s005 (1.09 MB TIF)
Figure S6 Sequence alignment of Normal Control VkI L12,
012/02, L5, VkII A19, A1, VkIII A27 and L2. Structure
determination and mutation analysis were done as described in
Figure S1.
Found at: doi:10.1371/journal.pone.0005169.s006 (0.81 MB TIF)
Figure S7 Sequence alignment of Normal Control VkIII L6 and
L2 VkIV B3. Structure determination and mutation analysis were
done as described in Figure S1.
Found at: doi:10.1371/journal.pone.0005169.s007 (0.42 MB TIF)
Figure S8 Sequence alignment of Normal Control VlI 1c, 1b,
VlII 2a2, 2e, VlIII 3h, VlVII 7b and VlIX 9a. Structure
determination and mutation analysis were done as described in
Figure S1.
Found at: doi:10.1371/journal.pone.0005169.s008 (0.59 MB TIF)
Figure S9 Sequence alignment of Multiple Myeloma Control
VlVI 6a, VlIII 3r, VlII 2a2, VkI 018/08, L12, VkII A19, and
VkIV B3. Structure determination and mutation analysis were
done as described in Figure S1.
Found at: doi:10.1371/journal.pone.0005169.s009 (0.69 MB TIF)
Figure S10 The total mutations were counted for each AL
patient and the fraction of those that were considered non-
conservative graphed. The majority of the AL Lambda patients
had a fraction of non-conservative mutations falling between 0.6
and 0.79, whether they were Lambda I, II and III or Lambda VI.
The majority of AL Kappa patients had a fraction of non-
conservative mutations falling between 0.4 and 0.59.
Found at: doi:10.1371/journal.pone.0005169.s010 (0.78 MB TIF)
Figure S11 Comparison of the number of non-conservative
mutations over total number of individuals between Multiple
Myeloma, normal kappas and normal lambdas (Data from
Figure 3).
Found at: doi:10.1371/journal.pone.0005169.s011 (0.47 MB TIF)
Acknowledgments
The authors wish to thank the Ramirez-Alvarado laboratory and the Mayo
Clinic Amyloid Interest group for helpful discussions and feedback.
Author Contributions
Conceived and designed the experiments: NL AD MRA. Performed the
experiments: TLP LAS RJC MRA. Analyzed the data: TLP AD MRA.
Wrote the paper: TLP NL AD MRA.
References
1. Buxbaum JN (2003) Diseases of protein conformation: what do in vitro
experiments tell us about in vivo diseases? Trends Biochem Sci 28: 585–592.
2. Ross CA, Poirier MA (2004) Protein aggregation and neurodegenerative disease.
Nat Med 10 Supplement: S10–S17.
3. Olsen KE, Sletten K, Westermark P (1998) Fragments of the constant region of
immunoglobulin light chains are constituents of AL-amyloid proteins. Biochem
Biophys Res Commun 251: 642–647.
4. Branden C, Tooze J (1999) Introduction to protein structure. New York:
Garland Publishing, Inc. 410 p.
5. Kyle RA, Gertz MA (1995) Primary systemic amyloidosis: clinical and
laboratory features in 474 cases. Semin Hematol 32: 45–59.
6. Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA (2001) The
tropism of organ involvement in primary systemic amyloidosis: contributions of
Ig V(L) germ line gene use and clonal plasma cell burden. Blood 98: 714–720.
7. Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, et al. (2003)
Immunoglobulin light chain variable (V) region genes influence clinical
presentation and outcome in light chain-associated amyloidosis (AL). Blood
101: 3801–3808.
8. Prokaeva T, Spencer B, Kaut M, Ozonoff A, Doros G, et al. (2007) Soft tissue,
joint, and bone manifestations of AL amyloidosis: clinical presentation,
molecular features, and survival. Arthritis Rheum 56: 3858–3868.
9. Wall J, Schell M, Murphy C, Hrncic R, Stevens FJ, et al. (1999)
Thermodynamic instability of human lambda 6 light chains: correlation with
fibrillogenicity. Biochemistry 38: 14101–14108.
10. Kim Y, Wall JS, Meyer J, Murphy C, Randolph TW, et al. (2000)
Thermodynamic modulation of light chain amyloid fibril formation. J Biol
Chem 275: 1570–1574.
11. Hurle MR, Helms LR, Li L, Chan W, Wetzel R (1994) A role for destabilizing
amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci U S A
91: 5446–5450.
12. Wetzel R (1997) Domain stability in immunoglobulin light chain deposition
disorders. Adv Protein Chem 50: 183–242.
13. Stevens FJ, Weiss DT, Solomon A (1999) Structural bases of light chain-related
pathology. Antibodies. pp 175–207.
14. Baden EM, Owen BA, Peterson FC, Volkman BF, Ramirez-Alvarado M, et al.
(2008) Altered dimer interface decreases stability in an amyloidogenic protein.
J Biol Chem 283: 15853–15860.
15. Dispenzieri A, Zhang L, Katzmann JA, Snyder M, Blood E, et al. (2008)
Appraisal of immunoglobulin free light chain as a marker of response. Blood
111: 4908–4915.
16. Stevens FJ (2000) Four structural risk factors identify most fibril-forming kappa
light chains. Amyloid 7: 200–211.
17. O’Nuallain B, Allen A, Kennel SJ, Weiss DT, Solomon A, et al. (2007)
Localization of a conformational epitope common to non-native and fibrillar
immunoglobulin light chains. Biochemistry 46: 1240–1247.
18. Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, et al.
(2006) Absolute values of immunoglobulin free light chains are prognostic in
patients with primary systemic amyloidosis undergoing peripheral blood stem
cell transplantation. Blood 107: 3378–3383.
19. Baden EM, Randles EG, Aboagye AK, Thompson JR, Ramirez-Alvarado M
(2008) Structural insights into the role of mutations in amyloidogenesis. J Biol
Chem 283: 30950–30956.
20. Abraham RS, Manske MK, Zuckerman NS, Sohni A, Edelman H, et al. (2007)
Novel analysis of clonal diversification in blood B cell and bone marrow plasma
cell clones in immunoglobulin light chain amyloidosis. J Clin Immunol 27:
69–87.
21. Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, et al. (1998)
Dose-intensive melphalan with blood stem-cell support for the treatment of AL
(amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood
91: 3662–3670.
22. Comenzo RL, Wally J, Kica G, Murray J, Ericsson T, et al. (1999) Clonal
immunoglobulin light chain variable region germline gene use in AL
amyloidosis: association with dominant amyloid-related organ involvement
and survival after stem cell transplantation. British Journal of Haematology 106:
744–751.
23. Sikkink LA, Ramirez-Alvarado M (2008) Biochemical and aggregation analysis
of Bence Jones proteins from different light chain diseases. Amyloid 15: 29–39.
24. Wally J, Kica G, Zhang Y, Ericsson T, Connors LH, et al. (1999) Identification
of a novel substitution in the constant region of a gene coding for an
amyloidogenic kappa1 light chain. Biochim Biophys Acta 1454: 49–56.
25. Arendt BK, Ramirez-Alvarado M, Sikkink LA, Keats JJ, Ahmann GJ, et al.
(2008) Biologic and genetic characterization of the novel amyloidogenic lambda
light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood 112:
1931–1941.
26. Welschof M, Terness P, Kolbinger F, Zewe M, Dubel S, Dorsam H, Hain C,
Finger M, Jung M, Moldenhauer G, et al. (1995) Amino acid sequence based
PCR primers for amplification of rearranged human heavy and light chain
immunoglobulin variable region genes. J Immunol Methods 179(2): 203–14.
27. Radzicka A, Pedersen L, Wolfenden R (1988) Influences of solvent water on
protein folding: free energies of solvation of cis and trans peptides are nearly
identical. Biochemistry 27: 4538–4541.
28. Schiffer M (1996) Molecular anatomy and the pathological expression of
antibody light chains. Am J Pathol 148: 1339–1344.
Structure and Mutations in AL
PLoS ONE | www.plosone.org 10 April 2009 | Volume 4 | Issue 4 | e5169